The discovery and clinical application of (-2) proPSA (P2PSA) have made PHI an important indicator for low-risk and intermediate-risk PCa screening, especially in PSA 2–20 ng/mL, in clinical practice [8,9]. The gene discussed is KLK3; the disease is posterior cortical atrophy.